411 related articles for article (PubMed ID: 21374691)
1. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
Pawlotsky JM
Hepatology; 2011 May; 53(5):1742-51. PubMed ID: 21374691
[TBL] [Abstract][Full Text] [Related]
2. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
3. Treatment failure with new hepatitis C drugs.
Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
[TBL] [Abstract][Full Text] [Related]
4. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
5. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
6. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
7. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
8. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
9. [Attempts to treat chronic hepatitis C with HCV protease inhibitor].
Pawłowska M
Przegl Epidemiol; 2011; 65(1):35-8. PubMed ID: 21735833
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis B and C in children.
El-Shabrawi M; Hassanin F
Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
[TBL] [Abstract][Full Text] [Related]
12. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.
Paeshuyse J; Dallmeier K; Neyts J
Curr Opin Virol; 2011 Dec; 1(6):590-8. PubMed ID: 22440916
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS; Spooner LM; Belliveau PP
Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
[TBL] [Abstract][Full Text] [Related]
17. Simeprevir for the treatment of chronic hepatitis C.
You DM; Pockros PJ
Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
[TBL] [Abstract][Full Text] [Related]
18. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
Macartney MJ; Irish D; Bridge SH; Garcia-Diaz A; Booth CL; McCormick AL; Labbett W; Smith C; Velazquez C; Tanwar S; Trembling P; Jacobs M; Dusheiko G; Rosenberg W; Haque T
Antiviral Res; 2014 May; 105():112-7. PubMed ID: 24594347
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with telaprevir and pegylated interferon suppresses both wild-type and resistant hepatitis C virus.
Lang L
Gastroenterology; 2007 Jan; 132(1):5-6. PubMed ID: 17241851
[No Abstract] [Full Text] [Related]
20. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
